A company can be worth one billion dollars on paper and functionally worthless at the same time. That is not a contradiction. It is the defining paradox of the zombie unicorn, a startup that achieved the most coveted valuation milestone in private markets and then discovered that the number, frozen in time by a single funding round years ago, had quietly stopped meaning anything at all.

Key Highlights

• By May 2026, 332 of 1,900 tracked unicorns had raised fresh capital at or below their peak valuation, with 212 now valued below the $1bn threshold, per Stanford University data.

• VC fundraising collapsed from $223bn in 2022 to $66bn in 2025 as the rate environment reversed and institutional appetite for illiquid private exposure contracted sharply.

• Investor veto rights over IPOs, anti-dilution triggers in down rounds, and rising public market listing thresholds have closed all three conventional exit routes simultaneously.

• PitchBook projects net valuation cuts of between $500bn and $1trn across the zombie cohort as firms reprice, seek acquirers, or wind down against a total estimated sector value of $5trn.

The term unicorn entered the startup vocabulary in 2013 when venture capitalist Aileen Lee used it to describe private companies valued above $1bn. At the time she counted 39 globally. By 2021, more than 350 startups joined the club in a single calendar year. Rarity had become a category.

The mechanics of how a startup earns a unicorn valuation matter here. The number is not a market price. It is a post-money valuation, the figure derived by adding the capital raised in a funding round to the pre-money valuation that investors and founders agreed upon beforehand. That valuation is assigned at a single point in time and carries no obligation to update until the company raises again. A startup that raised at a $1.2bn valuation in 2021 and has not raised since remains a unicorn in every major database, regardless of what has happened to its revenue, its market, or its competitive position in the years since.

A zombie unicorn is what emerges from that accounting gap. The company is alive in the sense that it still operates. It is effectively dead in the sense that it cannot raise at its old valuation, cannot access a credible exit, and has no clear path back to the growth that originally justified the number. The valuation is a record of a previous market that no longer exists.

How the Rate Cycle Created the Problem

Near-zero interest rates between 2019 and 2022 compressed returns across conventional asset classes. Institutional investors managing pension funds and endowments found themselves unable to meet return targets through fixed income alone. Capital flowed into venture funds in search of yield. VC fundraising peaked at $223bn in 2022.

That capital was deployed into startups at valuations anchored to growth narratives rather than earnings fundamentals. A company growing revenues at 80% annually in an environment where money had no cost could command almost any multiple. Discounted cash flow discipline, which is sensitive to interest rates, dissolved. Investors competed for allocations in rounds that sometimes closed within days.

The Federal Reserve's rate hiking cycle from 2022 onward reversed those conditions. As borrowing costs rose, the implied present value of cash flows years into the future compressed. VC fundraising fell to $66bn in 2025, less than a third of the 2022 peak. The pool of potential follow-on investors for unicorns looking to raise shrank alongside it.

The Three Exit Routes and Why All Three Are Blocked

A startup that cannot raise at its previous valuation has three conventional options: go public, find an acquirer, or raise a new private round at a lower valuation. For the zombie cohort, each carries structural obstacles that did not exist in the same form during the boom years.

The IPO route has become significantly more restrictive. US venture-backed listings fell from 198 in 2021 to 42 in 2022 and recovered only modestly to 48 in 2025. Passive investment strategies now dominate equity flows, analyst coverage of new listings has declined, and meaningful index inclusion requires a scale that almost no venture-backed company achieves at the point of listing. There is also a reputational calculation at play. The median unicorn IPO in 2025 priced at roughly its last private round valuation, with the majority of unicorn listings ending the year below their private peak. For investors carrying 2021 marks, listing publicly means formally confirming losses that private accounting has not yet required them to recognise.

Investor agreements add a further layer. Protective provisions, commonly known as veto rights, appeared in over 90% of venture rounds as of Q2 2025, according to Cooley data. These give preferred shareholders the contractual ability to block IPOs or acquisitions they consider value-destructive or premature. A fund that marked a portfolio company at $2bn and does not want to crystallise a loss at a $600m public offering has the tools to prevent it, at least temporarily.

The acquisition route faces its own constraints. Regulatory scrutiny of technology M&A has raised the cost and uncertainty of large deals. Buyer appetite has also shifted toward AI-native companies rather than ageing SaaS platforms or stalled consumer applications. The acquihire, where a company is purchased primarily for its engineering talent, delivers far less to financial investors than a strategic acquisition at a meaningful multiple.

Down rounds, which involve raising new equity at a lower valuation than the prior round, are the most available option but carry the most punishing internal consequences. Anti-dilution provisions, standard in the vast majority of term sheets, protect earlier investors by adjusting the conversion price of their preferred shares when a company raises below its previous valuation. Under the weighted average mechanism, which is the market standard in over 85% of deals, the adjustment is moderate. Under full ratchet anti-dilution, which reprices an investor's entire position to match the new lower price, the dilution to founders and employees can be severe enough to effectively strip them of meaningful economic interest in the company.

The Secondary Market Is Not a Solution

The private secondary market, where shareholders sell existing stakes in private companies to new buyers without the company issuing new shares, reached approximately $106bn in annualised transactions by late 2025, approaching the scale of the IPO market. Platforms including Forge Global and EquityZen have expanded access to secondary trading significantly.

For zombie unicorns specifically, the picture is more limited than those headline figures suggest. Secondary trading is heavily concentrated in a small number of high-profile AI companies. Companies carrying 2021 valuations trade at an average discount of 68% on the secondary market. Secondary sales at those levels confirm value destruction rather than provide a route around it. For investors holding liquidation preferences in the primary structure, selling at a 68% discount in the secondary market may deliver less than their contractual entitlement from a formal exit event.

What Comes Next

PitchBook estimates net valuation cuts of between $500bn and $1trn across the zombie cohort as firms reprice, seek acquirers, or close, against a total estimated sector value of approximately $5trn for non-top-ten unicorns globally.

Capital is not absent from private markets. In the first quarter of 2026 alone, AI startups raised $255.5bn globally, but three deals accounted for 67% of that figure. The concentration has compressed the timeline for everyone outside that group. VC investors who might previously have written a follow-on cheque to a SaaS company growing at 40% annually are directing that capital toward AI-native firms growing at multiples of that rate.

Some companies in the zombie cohort will find acquirers at reduced valuations. Some will restructure through negotiated down rounds. Some will pivot toward AI-native architectures aggressively enough to justify new investment. The majority will face a slower attrition, cutting costs, reducing headcount, and waiting for market conditions that may not return on the timeline their original investors assumed.

The billion-dollar label that once signalled arrival now sometimes signals the opposite: a valuation assigned in a different era, by investors operating under different assumptions, in a market that has since moved on entirely.